- Conditions
- Keloid
- Interventions
- Botulinum toxin type A, Vehicle
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- San Diego, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 254
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Bisphosphonate, Setrusumab
- Drug · Biological
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 2 Years to 6 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 10 more
- Conditions
- Dendritic Cell -Mediated Rheumatic Diseases
- Interventions
- VIB1116, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Anniston, Alabama • Clearwater, Florida • Jacksonville, Florida + 5 more
- Conditions
- Ehlers-Danlos Syndrome, Pain, Chronic
- Interventions
- White LED light, Green LED light
- Device
- Lead sponsor
- New York Institute of Technology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Old Westbury, New York
- Conditions
- Keloid
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Keloid, Keloid Scar Following Surgery
- Interventions
- Triamcinolone Injection, Triamcinolone Injection and 5-fluorouracil injection
- Drug
- Lead sponsor
- Our Lady of the Lake Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Asthma, Rheumatic Disease
- Interventions
- Drug: Acetaminophen, Drug: Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Obesity, Obesity, Morbid, Obesity, Primary, Gastro-Intestinal Disorder, Overweight and Obesity, Overweight, Overweight or Obesity, Diabetes Type 2, Diabetes Mellitus, Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemias, Sleep Apnea, GERD, Gastroesophageal Reflux, Musculoskeletal Pain Disorder, Cancer
- Interventions
- Blood Collection, Urine Collection, Tissue Sample Collection
- Diagnostic Test
- Lead sponsor
- Pichamol Jirapinyo, MD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
- Interventions
- Topical Beremagene Geperpavec, Placebo
- Biological · Other
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Rancho Santa Margarita, California • Stanford, California • Coral Gables, Florida
- Conditions
- Alport Syndrome
- Interventions
- BAY 3401016, Placebo
- Biological · Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 3 more
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- Topical beremagene geperpavec, Placebo gel
- Biological
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Polymyalgia Rheumatica, Inflammatory Diseases
- Interventions
- AIN457, ACZ885, Prednisone, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Scar Prevention, Scar Reduction
- Interventions
- AZX100 Drug Product, Placebo
- Drug
- Lead sponsor
- Capstone Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Austin, Texas
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- Not listed
- Lead sponsor
- Shire
- Industry
- Eligibility
- Not listed
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • New York, New York • Cincinnati, Ohio
- Conditions
- Keloid
- Interventions
- Removal of Keloid
- Procedure
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Keloid Scars, Hypertrophic Scars
- Interventions
- Cryotherapy with liquid nitrogen, Intralesional Triamcinolone 10 mg/ml
- Device · Drug
- Lead sponsor
- Sonal Choudhary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Cutaneous Sarcoidosis, Granuloma Annulare
- Interventions
- Tofacitinib 5 mg twice daily
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Small Fiber Neuropathy, Fabry Disease, Ehlers Danlos Syndrome, Mitochondrial Disease
- Interventions
- Sudoscan, Skin biopsy, QSART
- Device · Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 8 Years to 70 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Scleroderma
- Interventions
- ARFI-SVI Ultrasound
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- PTW-002 10 mg/g gel, Placebo
- Drug
- Lead sponsor
- Phoenicis Therapeutics
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Stanford, California • Worcester, Massachusetts • Cincinnati, Ohio
- Conditions
- Keloid
- Interventions
- Avotermin (Juvista), Placebo
- Drug
- Lead sponsor
- Renovo
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Granuloma Annulare
- Interventions
- Not listed
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- Not listed
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Osteogenesis Imperfecta
- Interventions
- AGA2115, Placebo
- Drug
- Lead sponsor
- Angitia Incorporated Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Lake Forest, California
- Conditions
- Cancer, Hematologic Disorder, Rheumatologic Disorder, Infertility
- Interventions
- Ovarian Cryopreservation
- Procedure
- Lead sponsor
- Vlad Radulescu
- Other
- Eligibility
- 12 Years to 41 Years · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 2
- States / cities
- Lexington, Kentucky • Louisville, Kentucky